三生制药(01530.HK) 宣布,附属公司沈阳三生与创新生物药公司映恩生物就HER2 ADC药物DB-1303达成合作协议,将获授予映恩生物开发的HER2 ADC药物DB-1303,多个适应症在中国大陆、香港和澳门的商业化权利。
沈阳三生将根据协议约定,向映恩生物支付首付款以及研发及销售里程碑付款。同时,映恩生物将继续负责相关适应症在合作区域的临床开发和注册等工作。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-13 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.